Compounded bioidentical HRT: what ACOG's 2023 consensus actually says

What's this video probably claiming?

Based on the caption citing ACOG Clinical Consensus No. 6 (Obstetrics & Gynecology, November 2023), Dr. Gonzalez is likely walking through the medical society's official position on compounded bioidentical hormone therapy (cBHT) for menopause. Given the TRT category tag, there's a reasonable chance he's also touching on testosterone use in women, a topic ACOG addresses directly in that document. He's probably framing the consensus as either validation or a measured critique of compounded hormone products, possibly arguing that individualized dosing through compounding fills gaps that FDA-approved products can't. Creators in this space frequently use professional society documents to lend credibility to arguments favoring compounded preparations over branded ones. That framing deserves scrutiny, because the actual ACOG document is more cautious than it often gets portrayed on social media.

What does the science actually say?

ACOG Clinical Consensus No. 6 explicitly states that compounded bioidentical hormones lack the rigorous efficacy and safety data required of FDA-approved therapies, and the society does not recommend them as a first-line option. The document acknowledges that testosterone may benefit women with hypoactive sexual desire disorder (HSDD), citing the 2019 Global Consensus Statement (Wierman et al., Journal of Clinical Endocrinology & Metabolism), but notes no testosterone product is currently FDA-approved for women in the United States. A 2022 Cochrane review (Islam et al.) found transdermal testosterone improved sexual function scores in postmenopausal women compared to placebo, but long-term safety data beyond 24 months remain sparse. The Endocrine Society's 2023 clinical practice guidelines similarly support short-term testosterone use for HSDD in women at doses approximating premenopausal physiological levels, roughly 150 to 300 micrograms per day transdermally, but flag that compounded products introduce unverifiable dose consistency.

Where does the social media noise diverge from clinical reality?

The loudest divergence is the implicit suggestion that compounded bioidentical hormones are safer or more "natural" than FDA-approved options because they share a molecular structure with endogenous hormones. ACOG explicitly rejects this reasoning. Bioidentical structure does not eliminate pharmacokinetic risk, and compounded pellets in particular have drawn regulatory attention for delivering supraphysiological hormone levels. A 2020 analysis published in Menopause (Pinkerton et al.) documented cases of androgenic side effects, including voice changes and clitoral enlargement, in women receiving testosterone pellet implants at doses exceeding clinical recommendations. The claim that compounding allows "personalized" dosing is also frequently overstated. Without standardized pharmacokinetic testing, personalization is often a marketing term rather than a clinical reality. ACOG's consensus draws this line clearly, and videos citing the document while softening that warning are misrepresenting it.

What should you actually know?

If you are a perimenopausal or postmenopausal woman considering hormone therapy, the evidence supports FDA-approved estrogen and progesterone formulations as first-line options for vasomotor symptoms. For sexual dysfunction specifically, testosterone has real supporting data, but no FDA-approved product exists for women yet, which means any prescription is off-label regardless of whether it comes from a compounding pharmacy or a licensed 503B outsourcing facility. Those two sources are not equivalent in quality oversight. Compounding pharmacies operate under state pharmacy board rules, not FDA manufacturing standards. If a clinician recommends testosterone for HSDD, the Endocrine Society guidance suggests using formulations and doses closest to what clinical trials actually tested, not pellets delivering variable and often higher exposures. Ask your provider what monitoring protocol they use for serum testosterone levels and what the target range is. A number matters here. Vague answers are a red flag.